TuHURA Biosciences (NASDAQ: HURA) backs stock fee for $50M credit line

Rhea-AI Filing Summary

TuHURA Biosciences, Inc. (HURA) reported results of its 2026 Annual Meeting and the approval of equity issued in connection with an existing credit facility. Stockholders approved issuing 1,878,287 common shares to Parkview Holdings One LLC as “Loan Fee Shares” under a previously agreed $50 million revolving credit facility, relying on private placement exemptions for an accredited investor.

Six directors were elected to serve until the 2027 annual meeting. An advisory vote approved named executive officer compensation, and stockholders indicated a preference for conducting future say-on-pay votes every three years. Cherry Bekaert LLP was ratified as independent auditor for the year ending December 31, 2026. A quorum was present, with 43,034,024 of 63,682,528 outstanding shares represented.

8-K Event Classification

3 items: 3.02, 5.07, 9.01

3 items

Item 3.02 Unregistered Sales of Equity Securities Securities

The company sold equity securities in a private placement or other unregistered transaction.

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Revolving credit facility size: $50 million Loan Fee Shares: 1,878,287 shares Shares outstanding: 63,682,528 shares +4 more

7 metrics

Revolving credit facility size $50 million Facility extended to the company by Parkview Holdings One LLC under the Loan Agreement dated April 21, 2026

Loan Fee Shares 1,878,287 shares Common shares to be issued to Parkview upon stockholder approval under the Fee Letter

Shares outstanding 63,682,528 shares Common stock outstanding and entitled to vote as of June 26, 2026 record date

Shares represented at meeting 43,034,024 shares Shares present in person or by proxy at the 2026 Annual Meeting, constituting a quorum

Nasdaq Proposal votes for 28,128,581 votes Votes cast in favor of approving issuance of Loan Fee Shares under Nasdaq Listing Rule 5635(d)

Say-on-pay votes for 26,125,280 votes Votes cast in favor of advisory approval of named executive officer compensation

Auditor ratification votes for 42,911,888 votes Votes for ratifying Cherry Bekaert LLP as independent auditor for fiscal year 2026

Key Terms

revolving credit facility, Nasdaq Listing Rule 5635(d), accredited investor, broker non-votes

4 terms

revolving credit facility financial

"Parkview agreed to extend a $50 million revolving credit facility to the Company"

A revolving credit facility is a type of loan that a business can borrow from whenever it needs money, up to a set limit. It’s like having a credit card for companies—allowing them to borrow, pay back, and borrow again as needed, providing flexibility for managing cash flow or funding short-term expenses.

Nasdaq Listing Rule 5635(d) regulatory

"to approve the issuance ... in accordance with Nasdaq Listing Rule 5635(d)"

Nasdaq Listing Rule 5635(d) is a stock-exchange rule that determines when a company must get shareholder approval before issuing new shares tied to conversions or exercises of existing convertible securities, options or warrants. It matters to investors because it controls potential dilution of their holdings and changes in voting power—think of it like a rule that decides whether a previously agreed‑upon coupon can be redeemed without asking the group again.

accredited investor regulatory

"issued solely to an “accredited investor,” as such term is defined in the Securities Act"

An accredited investor is an individual or entity that meets certain financial criteria, such as having a high income or significant net worth, allowing them to invest in private or less regulated investment opportunities. This status matters because it grants access to investments that are often riskier or less available to the general public, reflecting a higher level of financial knowledge or resources.

broker non-votes financial

"Name | For | Withheld | Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

FAQ

What did HURA stockholders approve about the Parkview Loan Fee Shares?

Stockholders approved issuing 1,878,287 TuHURA Biosciences common shares to Parkview Holdings One LLC as Loan Fee Shares. These shares relate to a previously agreed $50 million revolving credit facility and will be issued via a private placement to an accredited investor.

How large is TuHURA Biosciences (HURA)’s revolving credit facility with Parkview?

TuHURA Biosciences has a $50 million revolving credit facility with Parkview Holdings One LLC. As part of the related fee arrangement, stockholders approved issuing 1,878,287 Loan Fee Shares to Parkview under private placement exemptions.

Was there a quorum at TuHURA Biosciences (HURA)’s 2026 Annual Meeting?

Yes. A quorum was reached with 43,034,024 shares present out of 63,682,528 outstanding shares entitled to vote. This satisfied the requirement that at least one-third of voting power be represented for business to be conducted.

What say-on-pay decisions did HURA stockholders make at the 2026 meeting?

Stockholders approved the advisory vote on named executive officer compensation and chose a three-year frequency for future say-on-pay votes. This means TuHURA plans to hold advisory compensation votes on a triennial basis absent future changes.

Which auditor did TuHURA Biosciences (HURA) stockholders ratify for 2026?

Stockholders ratified Cherry Bekaert LLP as TuHURA’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification passed with 42,911,888 votes for, 39,928 against, and 82,208 abstentions.

How many directors were elected at TuHURA Biosciences (HURA)’s 2026 Annual Meeting?

Stockholders elected six directors: James Bianco, M.D., James Manuso, Ph.D., MBA, Alan List, M.D., George Ng, Robert E. Hoffman, and Craig Tendler, M.D. Each will serve until the 2027 Annual Meeting and until a successor is duly elected and qualified.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/19/2026 - 05:00 PM Accepted by SEC EDGAR 08/19/2026 - 05:00 PM Learn about SEC filing dates

0001498382falseTuHURA Biosciences, Inc./NV00014983822026-08-182026-08-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 18, 2026

TUHURA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-37823		99-0360497
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
10500 University Center Dr., Suite 110, Tampa, Florida				33612
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (813) 875-6600

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common stock, $0.001 par value		HURA		The Nasdaq Stock Market LLC (NASDAQ Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.02 Unregistered Sale of Equity Securities.

As previously disclosed in the Current Report on Form 8-K filed by TuHURA Biosciences, Inc. (the “Company”) with the Securities and Exchange Commission on April 22, 2026, on April 21, 2026, the Company entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC (“Parkview”), under which Parkview agreed to extend a $50 million revolving credit facility to the Company. In connection with the Loan Agreement, pursuant to a Fee Letter dated April 21, 2026 (the “Fee Letter”), the Company agreed to issue an aggregate of 1,878,287 shares of Company common stock (the “Loan Fee Shares”) to Parkview, subject to stockholder approval. As disclosed under the heading “Proposal Two—Nasdaq Proposal” in Item 5.07 of this Current Report on Form 8-K, the Company’s stockholders approved the issuance of the Loan Fee Shares at the 2026 Annual Meeting of the Stockholders (the “2026 Annual Meeting”). As a result of such stockholder approval, the Company will issue the Loan Fee Shares to Parkview.

The Company claims an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), for the private placement of the Loan Fee Shares, as the Loan Fee Shares will be issued solely to an “accredited investor,” as such term is defined in the Securities Act, and in reliance on the exemption from registration afforded by Section 4(a)(2) and/or Regulation D (Rule 506) under the Securities Act and corresponding provisions of state securities laws.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 18, 2026, the Company held the 2026 Annual Meeting. As of the June 26, 2026 record date for the determination of the stockholders entitled to notice of, and to vote at, the 2026 Annual Meeting, 63,682,528 shares of common stock of the Company were outstanding and entitled to vote, with each share entitled to one vote.

Present at the 2026 Annual Meeting, in person or by proxy, were holders of 43,034,024 shares of the Company’s common stock, representing at least one-third of the voting power of the capital stock issued and outstanding and entitled to vote at the 2026 Annual Meeting as of June 26, 2026, which constituted a quorum for the transaction of business. At the 2026 Annual Meeting, the Company’s stockholders voted on the following proposals:

Proposal One—Election of Directors: To elect six directors—James Bianco, M.D., James Manuso, Ph.D., MBA, Alan List, M.D., George Ng, Robert E. Hoffman and Craig Tendler, M.D.—to serve until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified. In accordance with the voting results listed below, each of the six director nominees was elected by the requisite vote of the Company’s stockholders.

Name		For				Withheld				Broker Non-Votes
James Bianco, M.D.		28,358,439				371,893				14,303,692
James Manuso, Ph.D., MBA		28,351,424				378,908				14,303,692
Alan List, M.D.		28,404,403				325,929				14,303,692
George Ng		26,507,318				2,223,014				14,303,692
Robert E. Hoffman		28,322,397				407,935				14,303,692
Craig Tendler, M.D.		28,403,520				326,812				14,303,692

Proposal Two—Nasdaq Proposal: To approve the issuance of 1,878,287 shares of the Company’s common stock pursuant to the Fee Letter, in accordance with Nasdaq Listing Rule 5635(d). In accordance with the voting results listed below, the Nasdaq Proposal was approved by a majority of the votes cast.

For		Against		Abstain		Broker Non-Votes
28,128,581		517,896		83,855		14,303,692

Proposal Three—Executive Compensation Proposal: To conduct an advisory vote to approve the compensation of the Company’s named executive officers. In accordance with the voting results listed below, the advisory vote on named executive officer compensation was approved by a majority of the votes cast.

For		Against		Abstain		Broker Non-Votes
26,125,280		2,484,951		120,101		14,303,692

Proposal Four—Say-on-Frequency: To conduct an advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers. In accordance with the voting results listed below, three years received the highest number of votes cast.

One Year		Two Years		Three Years		Abstain	Broker Non-Votes
13,945,985		101,587		14,472,313		211,447	14,303,692

Proposal Five—Auditor Ratification: To ratify the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. In accordance with the voting results listed below, the appointment of Cherry Bekaert LLP was ratified by a majority of the votes cast.

For		Against		Abstain
42,911,888		39,928		82,208

Proposal Six—Adjournment Proposal: To transact such other business as may properly come before the stockholders at the 2026 Annual Meeting. Although the Adjournment Proposal received sufficient votes to be approved, no motion to adjourn the 2026 Annual Meeting was made because no adjournment was determined to be necessary or appropriate.

For		Against		Abstain		Broker Non-Votes
28,176,545		481,843		71,944		14,303,692

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Exhibit Title
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		TUHURA BIOSCIENCES, INC.
Date: August 19, 2026		By:		/s/ Dan Dearborn
				Dan Dearborn
				Chief Financial Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 30.1 KB